Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX8DC2)

Drug Name

Homorisedronate Drug Info

Synonyms

NE 58051; 104261-69-0; NE-58051; CHEMBL293522; [1-hydroxy-3-(pyridin-3-yl)propane-1,1-diyl]bis(phosphonic acid); HRX; AC1L2TXU; SCHEMBL8710665; 3-(3-Pyridyl)-1-hydroxypropylidene bisphosphonic acid; (1-Hydroxy-3-(3-pyridinyl)propylidene)bisphosphonic acid; DTXSID70146363; 1-hydroxy-3-(3-pyridyl)propylidene-1,1-bisphosphonic acid; ILROXFQHACCDLA-UHFFFAOYSA-N; BDBM50098382; 3-(3-Hydroxy-3,3-bis-phosphono-propyl)-pyridinium; 3-(3-pyridyl)-1-hydroxy-propane-1,1-bisphosphonate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 128523
CAS Number: CAS 104261-69-0
TTD Drug ID: DMX8DC2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Geranyltranstransferase (FDPS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zoledronate	DMIXC7G	Adenocarcinoma	2D40	Approved	[2]
Minodronate	DM50PMY	Osteoporosis	FB83.0	Approved	[3]
Ibandronate	DM0QZBN	Hypercalcaemia	5B91.0	Approved	[2]
Alendronate	DMY2KX9	Bone Paget disease		Approved	[2]
Pamidronate	DMB4AVP	Bone Paget disease		Approved	[4]
Incadronate	DM3DSVJ	Hypercalcaemia	5B91.0	Approved	[5]
Risedronate	DM5FLTY	Bone Paget disease		Approved	[6]
NERIDRONIC ACID	DMMPG5V	Bone disease	FC0Z	Approved	[7]
Zarnestra	DMF30HL	Acute myeloid leukaemia	2A60	Phase 3	[8]
GERANYLGERANYL DIPHOSPHATE	DMJZ0AM	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Geranyltranstransferase (FDPS)	TTIKWV4	FPPS_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem. 2001 Sep 7;276(36):33930-7.
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
3	Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem. 2010 May 13;53(9):3454-64.
4	Detection of nonsterol isoprenoids by HPLC-MS/MS. Anal Biochem. 2008 Dec 1;383(1):18-24.
5	Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42.
6	Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem. 2002 Jul 4;45(14):2904-14.
7	Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of hu... J Med Chem. 2008 Apr 10;51(7):2187-95.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.